We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
No guessing. No dead ends. We curate the global research on women's aging, verify the science with our clinical team, and route every finding to the exact intervention — supplement or prescription — available to you today.
We do not run a research lab. We translate it. Every Kindr protocol maps to peer-reviewed work from institutions actively defining the science of aging — including the Sinclair Lab at Harvard Medical School (Blavatnik Institute · Department of Genetics), the Barzilai lab at Albert Einstein, and the Kaeberlein lab at the University of Washington.
External links are provided as scientific reference only. Kindr Health is not affiliated with, endorsed by, or sponsored by the Sinclair Lab, Harvard Medical School, Albert Einstein College of Medicine, or the University of Washington.
The decade to protect the ovary, the mitochondria, and the microbiome — before the first symptom.
NAD+ concentrations begin measurable decline in the mid-30s, throttling sirtuin activity and mitochondrial ATP output long before overt menopause symptoms appear.
Physician-prescribed subcutaneous NAD+ course to restore cofactor supply for sirtuin and PARP repair pathways.
Type I and III collagen synthesis begin declining in the early 30s. Late intervention only slows further loss — early loading measurably preserves dermal density.
Hydrolyzed marine collagen with vitamin C cofactor for dermal, tendon, and joint matrix support.
Ovarian reserve, thyroid axis, and metabolic biomarkers begin quiet drift in the mid-30s. Without a baseline panel, the first "symptom" is a decade of missed data.
At-home CLIA-certified labs covering estradiol, FSH, LH, testosterone, TSH/free T3/T4, fasting insulin, HbA1c, and lipid subfractions.
Intracellular glutathione — the master antioxidant — falls sharply through the 30s, exposing mitochondria and DNA to oxidative damage that later drives inflammaging.
Clinician-prescribed reduced glutathione course to replenish redox reserve; pairs with NAD+ for full electron-chain support.
Musculoskeletal repair rate drops before strength does. BPC-157 and TB-500 have consistent preclinical data on tendon, ligament, and gut-lining regeneration.
Physician-directed cytoprotective peptide pair for connective-tissue repair and GI-mucosa integrity.
Estradiol becomes erratic. Insulin sensitivity and mood are the first casualties.
Peer-reviewed data shows the perimenopausal decline in estradiol impairs insulin sensitivity and shifts fat storage toward the viscera — even without a change in diet or activity.
DIM + calcium-d-glucarate formulation to support healthy estrogen metabolism and reduce fluid retention linked to estrogen dominance.
Luteal-phase progesterone withdrawal downregulates serotonergic tone in a subset of women, driving the mood, sleep, and cognitive collapse recognized as PMDD.
Clinician-directed luteal-phase SSRI dosing combined with inositol and targeted micronutrients, prescribed via telehealth after intake.
Somatotropic output drops roughly 14% per decade after 30. The consequences — visceral fat gain, poor recovery, thinning skin — accelerate through perimenopause.
Clinician-prescribed growth-hormone-releasing peptides that restore pulsatile GH secretion without supraphysiologic HGH exposure.
Falling progesterone reduces GABAergic tone; declining estradiol destabilizes thermoregulation. Slow-wave and REM sleep are the first to fragment.
Non-hormonal magnesium-glycinate and L-theanine stack for nightly use; DSIP peptide available via clinical intake for resistant cases.
Tesamorelin is the only GHRH analog with FDA-recognized data specifically reducing visceral adipose tissue — the fat pattern that appears in perimenopause independent of caloric intake.
Clinician-prescribed GHRH analog course, monitored with waist circumference and lipid tracking.
Perimenopause is diagnosed retroactively. Structured symptom capture — cycle length, flow, mood, sleep, hot flashes — is the single best signal for personalizing treatment.
Clinician-designed daily tracker built for perimenopause pattern recognition, reviewed at every telehealth visit.
Perimenopausal shifts in CYP1A1/1B1 balance favor the 4-hydroxy estrogen pathway — the pattern linked to breast-tissue stress and estrogen-dominance symptoms.
Physician-formulated daily multi with B-complex methylation cofactors, magnesium, and micronutrients supporting healthy estrogen metabolism.
Collagen, muscle, bone, and skin lose their scaffolding. Every intervention here compounds.
Loss of estradiol accelerates collagen cross-linking via glycation and halts fibroblast turnover. The extracellular matrix stiffens and thins — clinically visible as crepe skin and slow wound healing.
Topical peptide serum designed to interrupt advanced glycation end-products and support the extracellular matrix.
Semaglutide and tirzepatide reduce weight — but roughly 25–40% of the loss can come from lean muscle. In menopausal women this compounds sarcopenia and metabolic slowdown.
Clinician-directed GLP-1 protocol paired with muscle-preserving peptides, creatine, and protein-adequacy coaching. Prescribed only after medical intake.
Estrogen drives dermal fibroblast activity, follicular pigment, and copper-dependent lysyl oxidase cross-linking. Its loss produces the classic menopausal thinning of skin and hair.
Copper-peptide protocol clinically studied for dermal remodeling, wound healing, and follicular restoration.
Hypoactive Sexual Desire Disorder in menopausal women is driven by falling estradiol, testosterone, and central melanocortin tone — not psychology alone.
FDA-recognized melanocortin agonist for on-demand desire, prescribed after intake and pairs with topical estradiol.
GSM affects up to 70% of post-menopausal women — vaginal dryness, atrophy, and recurrent UTIs driven by local estrogen loss.
Hyaluronic-acid intimate moisturizer for daily use, paired with an oral supplement supporting urogenital tissue integrity. Prescription topical estradiol available via intake.
Vasomotor symptoms are driven by hypothalamic KNDy neurons and CGRP-mediated vasodilation, not simple estrogen loss. Rapid rescue is possible without systemic hormones.
On-demand cooling mist with clinically studied botanicals for rapid vasomotor relief; pairs with prescription non-hormonal options via intake.
Lean-mass loss after 50 predicts all-cause mortality more strongly than BMI. Anabolic resistance in menopause requires higher leucine thresholds and myostatin control.
Leucine-loaded whey isolate for daily anabolic threshold; Follistatin-344 peptide available via clinical intake for advanced myostatin suppression.
The 50s are when multi-system decline compounds. Isolated interventions underperform coordinated protocols targeting hormones, muscle, sleep, and mitochondria in parallel.
Curated core bundle — foundational multi, sleep support, and cycle tracker — built for the first 90 days of menopause management.
Autonomic tone, cognition, and inflammatory load define the next thirty years.
Post-menopausal microglial activation and HPA-axis dysregulation lock the CNS in sympathetic drive, sustaining insomnia, tinnitus, and adrenal fatigue.
Physician-directed low-dose naltrexone plus guanfacine protocol, with sleep architecture monitoring. Prescription-only, via intake.
Post-menopausal estrogen loss reduces cerebral glucose metabolism and BDNF expression, producing the recall and word-finding deficits reported by 60%+ of women.
BDNF-upregulating peptides prescribed after neurocognitive intake, paired with omega-3 and B-complex support.
Thymic involution and NK-cell exhaustion drive a chronic low-grade inflammatory state that predicts cardiovascular, oncologic, and neurodegenerative risk.
Physician-prescribed thymic peptide with decades of clinical safety data for immune modulation. Requires eligibility screen.
5-Amino-1MQ inhibits NNMT to preserve NAD+ and reactivate AMPK — a validated target for reversing age-related metabolic inflexibility and adipose expansion.
Oral NNMT inhibitor course, physician-prescribed, monitored with fasting insulin and body-composition tracking.
ARA-290 is an EPO-derived peptide that binds the tissue-protective receptor complex, reducing neuroinflammation and neuropathic pain without hematopoietic side effects.
Physician-prescribed peptide for chronic inflammatory and neuropathic conditions, with pre-treatment eligibility screening.
The molecular substrate underneath every symptom above.
Senescent cells accumulate with age and secrete the SASP — inflammatory factors that accelerate bone resorption and matrix degradation. Estrogen loss compounds the effect.
A physician-supervised senolytic and mineral support protocol targeting bone-density preservation. Requires eligibility screening.
Cardiolipin peroxidation degrades inner-mitochondrial-membrane geometry — the electron transport chain leaks, ATP output falls, and ROS climbs.
Cardiolipin-stabilizing (SS-31) and mitochondrial-derived (MOTS-c) peptides prescribed for metabolic and cognitive resilience.
Telomere shortening tracks with biological (not chronological) age. Epithalon and pineal peptides have decades of Russian and European data on telomerase activation.
Cyclic pineal-derived peptide course, physician-prescribed, with blood-panel monitoring across the treatment window.
Humanin is a 24-aa mitochondrial-derived peptide with in-vivo cytoprotective and insulin-sensitizing signaling. Circulating levels correlate inversely with biological age.
Emerging mitochondrial peptide course, physician-supervised, aligned with SS-31 / MOTS-c for full bioenergetic coverage.
NK cells and CD8+ T-cells clear senescent cells. Thymic peptides like Thymosin Alpha-1 restore this surveillance, augmenting senolytic response beyond drug therapy alone.
Thymosin Alpha-1 paired with VIP or LL-37 depending on inflammatory phenotype, prescribed after immune panel screening.
The SASP drives fibrotic remodeling across kidney, liver, and vascular tissue. Peptide-based anti-fibrotic strategies are the current translational frontier.
Physician-directed evaluation for candidate peptides (Cagrilintide, MOTS-c, SS-31) matched to tissue-specific fibrotic risk from lab panel.
All research on this page is curated from peer-reviewed public knowledge and reviewed by the Kindr Health clinical team. Products described as supplements are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. Telehealth protocols require a medical intake consultation with a licensed clinician. Kindr Health Inc. · NPI 1609792902 · LegitScript certified · NAMS-aligned. Individual results vary.